Introduction: To assess the clinical impact of the Types of Epithelial ovarian tumour designated as Type I and II
according to Immunohistochemistry and Histopathology to study the association of Types of EOC with stage,
cytoreductability and progression free survival rate.
Methods: This study was conducted in the Department of Gynaecological oncology, Amrita Institute of Medical Sciences,
Kochi, Kerala, India in year 2017–2018 after obtaining the approval of the Institute Ethical Review Board committee.
Patients were asked to sign an informed written consent after explaining the need for the procedure, their possible
outcomes and the significance of the results. No new intervention was required in this study. All patients with Epithelial
ovarian cancer that was surgically treated (Both Primary delbulking and interval debulking surgery) in the Dept. of
Gynaecological Oncology were recruited in this study. Intraoperative mapping of pattern of distribution of disease was
done and the patients were divided into 3 Groups. Group A (Pelvis, nodes), Group B (omentum, peritoneum,
hemidiaphragm, surface liver), Group C (Mesentry, Porta hepatic, Lesser sac). If disease was found to be extensive
(Fagotti>8/PCI>17) these patients underwent Neoadjuvant cheomotherapy with Paclitaxil and Carboplatin and then
assessed for interval surgery. Residual disease was defined as R0-no residual macroscopic disease after surgery, R1-0.1-
0.5cm residual disease, R2-0.5-1cm, R3>1cm Stages are defined according to the FIGO classification WHO 2014 criteria
(I–IV), stage I/II is considered early FIGO stage, and stage III/IV, where the tumor has spread beyond the pelvic region, as
late FIGO stage. The categories of grade are well-differentiated (Grade 1) moderately differentiated (Grade 2), and poorly
differentiated (Grade 3). Grade 1 is considered as low-grade tumors and Grades 2-3 as high-grade tumors. Histologic
types were defined as serous adenocarcinoma, mucinous adenocarcinoma, endometrioid adenocarcinoma, clear cell
neoplasms, carcinosarcoma, transitional/Brenner tumors, mixed tumors, or undifferentiated carcinomas along with their IHC markers (p53, WT 1, ER, Napsin) were obtained from their histopathology reports. All pathologic diagnoses were
given by our dedicated Onco-pathologists. Kaplan-Meier and logistic/Cox-regression analyses were performed to assess
the impact of histological type on surgical outcome and survival.
Results: All EOC patients (n=101) reporting to our Dept. of Gynaecological oncology who underwent tumour debulking in
our institution (09/2016–012/2018) were classified into one of two groups: type I tumours (n=36); composed of lowgrade serous, low-grade endometrioid, clear cell, mucinous and transitional carcinomas; and Type II tumours (n=65)
composed of high-grade serous, high-grade endometrioid, undifferentiated and malignant mixed-mesodermal tumours.
Primary debulking surgery rate (PDS) with complete cytoreduction (R0) was more in Type I EOC, with almost 91.2% vs
67.4% in Type II EOC showing clinically and statistical significance (p value.0.016). Also R1/R2 (R1-0.1-0.5cm residual
disease, R2-0.5-1cm residual disease), was more in Type II compared to Type I showing borderline statistical significance
(p value.0.566). According to the pattern of distribution, PDS and IDS was assessed in all the 3 Groups in Type I & II EOC.
Type I had 94.4% PDS compared with 66.2% Type II in Group A (pelvis, nodes) showing clinically and statistical
significance (p value 0.001.). In group B (omentum, peritoneum, hemidiphram, liver) Type I had 88.2% PDS vs 60% in
type II showing clinically and statistical significance (p value 0.038). In group C (Porta, mesentry, lesser sac) Type I had
75% PDS vs 63.2% in type II showing clinically and statistical significance(p value 0.0676). According to the pattern of
distribution, cytoreductability (R0/R1,2) was assessed in all the 3 Groups in type I & II EOC. Type I had 8.8% R1/2
compared with 32.6% Type II in Group A (pelvis, nodes) showing clinically and statistical significance (p value 0.016). In
group B (omentum, peritoneum, hemidiphram, liver) Type I had 13.3% R1/2 vs 51.9% in type II showing clinically and
statistical significance(p value 0.044). In group C (Porta, mesentry, lesser sac) Type I had 33.3%R1/2 vs 58.3% in type II,
not showing statistical significance (p value 0.429).
Conclusion: Type I EOC patients appear to present at earlier stages with younger age of presentation, their distribution
in group B (Omentum, Peritoneum, Surface Liver, Hemidiaphragm) has a significant p value in relation to their
cytoreductability (R0,R1/2). However, Progression free survival analysis an overall survival was not significant due to
the short follow up interval.
Below is the link to read this article
https://medwinpublishers.com/OAJG/OAJG16000178.pdf
Below is the link to read this article
https://medwinpublishers.com/OAJG/OAJG16000178.pdf
